ImmunoCellular Investor Presentation


Published on

IMUC is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

Published in: Business, Technology
1 Comment
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

ImmunoCellular Investor Presentation

  1. 1. January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB
  2. 2. SEC Disclaimer Statement <ul><li>This presentation contains certain “forward-looking statements” (statements as to matters other than historical facts) as defined in the Private Securities Litigation Reform Act and in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events, projections or results described in the forward-looking statements. These risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. </li></ul>January 2010
  3. 3. Mission <ul><li>To develop new immune-based products to target cancer stem cells </li></ul>January 2010
  4. 4. Cancer Stem Cells: Good Guys Turned Bad <ul><li>Cancers originate in tissue progenitor cells or normal stem cells through dysregulation of the self-renewal process </li></ul><ul><li>Throughout tumorigenesis CSCs drive tumor growth </li></ul>January 2010 Targeting CSCs may significantly delay or prevent disease recurrences. Normal Stem Cell mutations Cancer Stem Cell Mature Tissue Bulk Tumor Progenitor cells
  5. 5. Technology Overview: Utilizing Both Arms of Immune System <ul><li>ACTIVE IMMUNOTHERAPIES </li></ul><ul><li>Cellular Vaccine (ICT-107) </li></ul><ul><ul><li>Dendritic cell-based vaccine to elicit persistent and targeted T cell immune response against tumor-associated /CSC antigens </li></ul></ul><ul><ul><li>Phase I trial recently completed in glioblastoma multiforme </li></ul></ul><ul><ul><li>CSC Antigen Vaccine (ICT-121) </li></ul></ul><ul><ul><li>Platform technology for cancer stem cells </li></ul></ul><ul><ul><li>Peptide-based, off-the-shelf vaccine (peptide plus adjuvant) </li></ul></ul><ul><ul><li>IND to be filed in second half of 2010 </li></ul></ul><ul><li> </li></ul><ul><li>ANTIBODY IMMUNOTHERAPIES </li></ul><ul><ul><li>Antibody therapeutics targeting novel cancer antigens and cancer stem cells </li></ul></ul><ul><ul><li>DIAAD: platform technology for cancer antigens </li></ul></ul>January 2010
  6. 6. ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer
  7. 7. January 2010 Significant Improvement in Progression-Free Survival (Compared to Historical Controls Using Standard of Care) Radiation + Temozolomide* Radiation + Temozolomide +ICT-107 <ul><li>Stupp et al, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, </li></ul><ul><li>New England Journal of Medicine, March 2005 </li></ul>
  8. 8. Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)
  9. 9. ICT-121: Cancer Stem Cell Vaccine <ul><li>Peptide-based vaccine targeting CD133 antigen present on CSCs </li></ul><ul><li>Initial indication in glioblastoma </li></ul><ul><li>Off-the-shelf, peptide-based vaccine </li></ul><ul><li>IND to be filed in H2 2010 </li></ul><ul><li>May also be applicable to pancreatic, lung, colon, renal, melanoma, and breast cancers </li></ul><ul><li>Only company developing an active immunotherapy platform targeting CSCs </li></ul>January 2010 Potential Blockbuster Product
  10. 10. Summary of Antibody Programs January 2010 <ul><li>ICT-109: Antibody targeting small-cell lung cancer and pancreatic cancers </li></ul><ul><ul><li>High affinity (10-100 fold higher) </li></ul></ul><ul><ul><li>Humanized </li></ul></ul><ul><ul><li>In-vivo and in-vitro efficacy </li></ul></ul><ul><li>ICT-69: Multiple myeloma and ovarian cancer </li></ul><ul><ul><li>Novel target </li></ul></ul><ul><ul><li>In-vivo and in-vitro efficacy </li></ul></ul><ul><ul><li>License option agreement with Roche </li></ul></ul><ul><li>CSC Antibodies: Under development using proprietary CSC lines </li></ul>
  11. 11. Value Creation Catalysts in Next 12 Months <ul><li>Clinical </li></ul><ul><ul><li>Initiate Phase II clinical trials for ICT-107 (H2 2010) </li></ul></ul><ul><ul><li>IND filing for ICT-121 for glioblastoma in US (H2 2010) </li></ul></ul><ul><li>Regulatory </li></ul><ul><ul><li>Orphan Drug Application for ICT-107 (H1 2010) </li></ul></ul><ul><li>Business Development </li></ul><ul><ul><li>Potential partnering of ICT-107 and/or ICT-109 in 2010 </li></ul></ul><ul><ul><li>Additional Roche licensing payments for ICT-69 in 2010 </li></ul></ul>January 2010
  12. 12. Management Team <ul><li>Manish Singh, PhD , President and CEO </li></ul><ul><ul><ul><li>California Technology Ventures, Cell Genesys, Chiron-Viagene, Genetic Therapy Inc (Novartis) </li></ul></ul></ul><ul><li>John Yu, MD , Chairman and CSO </li></ul><ul><ul><ul><li>Neurosurgeon at Cedars-Sinai Medical Center, Mass General Hospital, Harvard Medical School </li></ul></ul></ul><ul><li>Jim Bender, PhD, MPH , VP of Clinical Development </li></ul><ul><ul><ul><li>IDM Pharma, Baxter Healthcare </li></ul></ul></ul><ul><li>C. Kirk Peacock, CPA , CFO </li></ul><ul><ul><ul><li>CytRx, DigitalMed, </li></ul></ul></ul>January 2010
  13. 13. Key Opinion Leaders <ul><li>Keith Black, MD , Head of Scientific Advisory Board </li></ul><ul><li>Head of Neurosurgery, Cedars-Sinai Medical Center </li></ul><ul><li>George Peoples, MD , Member of Scientific Advisory Board </li></ul><ul><li>Director of Cancer Vaccines, US Military Cancer Institute </li></ul><ul><li>Robert Martuza, MD , Member Board of Directors </li></ul><ul><li>Professor of Neurosurgery, Harvard Medical School, and Chief of Neurosurgery, Massachusetts General Hospital </li></ul><ul><li>Sherie Morrison, PhD , Member of Scientific Advisory Board Chair, Dept of Microbiology, Immunology and Molecular Genetics, UCLA </li></ul>January 2010
  14. 14. Financial Position and Capitalization <ul><li>Cash: $1.4 Million (Dec 31st, 2009) </li></ul><ul><li>Outstanding debt: $0 </li></ul><ul><li>Current burn rate: $600K/quarter </li></ul><ul><li>Shares outstanding: 14.6 million </li></ul><ul><li>Current share price: $1.00 </li></ul><ul><li>Current market cap: $14.6 million </li></ul><ul><li>Options outstanding : 9.7 million; average weighted average exercise price of $1.00 </li></ul><ul><li>Commitment from </li></ul><ul><li>Socius Capital: $10 million at market price </li></ul>January 2010
  15. 15. Summary <ul><li>Well positioned to become a complete immune solutions company targeting cancer </li></ul><ul><li>Unique technology based on cancer stem cells </li></ul><ul><li>Strong scientific and clinical expertise </li></ul><ul><li>Strong IP position covering CSCs and MAbs </li></ul><ul><li>4 clinical trials planned in next 3 years targeting brain, pancreatic, breast and ovarian cancers </li></ul><ul><li>Additional partnering opportunities in 2010 </li></ul><ul><li>Potential for a 3-5 X capital return to investors </li></ul>January 2010